Compare Incyte Corporation (INCY) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Energy Select Sector SPDR Fund — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Energy Select Sector SPDR Fund trades at $58.3. The key difference: Incyte Corporation is trading nearer its 52-week high, Energy Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| INCY | XLE | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | — |
52-Week High | $118.52 | $62.57 |
52-Week Low | $67.38 | $42.12 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
XLE is trading at $57.96, up 0.49% with a bullish technical signal supported by strong moving average indicators. The energy ETF benefits from record refiner margins and geopolitical tensions driving oil prices higher. Recent news highlights XLE as a top-performing sector SPDR with 21% year-to-date gains, though RSI levels suggest potential overbought conditions near-term.
The energy sector outlook remains positive with Q2 earnings growth expectations and strong institutional support, though investors face risks from oil price volatility and geopolitical uncertainty. Technical resistance at $58-59 may limit immediate upside, while sector rotation and clean energy competition present longer-term considerations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
